[{"data":1,"prerenderedAt":268},["ShallowReactive",2],{"drug-ceftriaxone":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":22,"regimens":38,"contraindications":136,"warnings":146,"renal":147,"monitoring":148,"interactions":149,"review":150,"examples":153,"atc":185,"iran":187,"links":211,"populations":229,"usApproval":263},"ceftriaxone",1,{"fa":7,"en":8},"سفتریاکسون","Ceftriaxone","anti-infectives",{"fa":11,"en":12},"سفالوسپورین نسل سوم","Third-generation cephalosporin",[14],{"name":15,"market":16},"Rocephin","US",[18,19,7,20,21],"rocephin","روسفین","سفتریاکسان","سفتریاکسون آمپول",[23],{"id":24,"form":25,"route":26,"label":27,"concentration":28,"markets":31,"refs":32},"im-250","powder-for-injection","im","IM: reconstituted to 250 mg\u002FmL (per label table)",{"amount":29,"unit":30,"perVolumeMl":5},250,"mg",[16],[33,36],{"source":34,"section":35},"fda-ceftriaxone","Dosage and Administration, Intramuscular Administration",{"source":34,"section":37},"How Supplied",[39,67,78,96,111],{"id":40,"disease":41,"label":42,"population":45,"type":49,"unit":30,"dose":50,"refs":53,"limits":56,"notes":60},"adult","susceptible-bacterial-infection",{"fa":43,"en":44},"بزرگسال: ۱ تا ۲ g یک بار در روز","Adults: 1–2 g once daily",{"minAge":46},{"value":47,"unit":48},18,"year","fixed",{"perDose":51,"perDoseMax":52,"dosesPerDay":5},1000,2000,[54],{"source":34,"section":55},"Dosage and Administration, Adults",{"maxPerDay":57,"refs":58},4000,[59],{"source":34,"section":55},[61],{"text":62,"refs":65},{"fa":63,"en":64},"یا در دو نوبت مساوی. حداقل ۲ روز پس از رفع علائم ادامه؛ معمولاً ۴ تا ۱۴ روز؛ استرپتوکوک پیوژنز حداقل ۱۰ روز.","Or in two equal doses. Continue ≥2 days after symptoms resolve; usually 4–14 days; S. pyogenes at least 10 days.",[66],{"source":34,"section":55},{"id":68,"disease":68,"label":69,"population":72,"type":49,"unit":30,"dose":74,"refs":75,"durationDays":77},"gonorrhea",{"fa":70,"en":71},"سوزاک بدون عارضه: ۲۵۰ mg عضلانی تک‌دوز","Uncomplicated gonorrhoea: 250 mg IM single dose",{"minAge":73},{"value":47,"unit":48},{"perDose":29,"dosesPerDay":5},[76],{"source":34,"section":55},{"min":5,"max":5},{"id":79,"disease":80,"label":81,"population":84,"type":86,"unit":30,"dose":87,"refs":89,"limits":92,"durationDays":95},"aom","acute-otitis-media",{"fa":82,"en":83},"اوتیت میانی حاد — کودکان: ۵۰ mg\u002Fkg عضلانی تک‌دوز (حداکثر ۱ g)","Acute otitis media — children: 50 mg\u002Fkg IM single dose (max 1 g)",{"maxAge":85},{"value":47,"unit":48},"weightBased",{"perKgPerDay":88,"dividedDoses":5},50,[90],{"source":34,"section":91},"Dosage and Administration, Pediatric Patients",{"maxPerDose":51,"refs":93},[94],{"source":34,"section":91},{"min":5,"max":5},{"id":97,"disease":98,"label":99,"population":102,"type":86,"unit":30,"dose":104,"refs":106,"limits":108},"sssi","skin-soft-tissue-infection",{"fa":100,"en":101},"عفونت پوست — کودکان: ۵۰ تا ۷۵ mg\u002Fkg\u002Fday یک بار (حداکثر ۲ g\u002Fday)","Skin infection — children: 50–75 mg\u002Fkg\u002Fday once (max 2 g\u002Fday)",{"maxAge":103},{"value":47,"unit":48},{"perKgPerDay":88,"perKgPerDayMax":105,"dividedDoses":5},75,[107],{"source":34,"section":91},{"maxPerDay":52,"refs":109},[110],{"source":34,"section":91},{"id":112,"disease":113,"label":114,"population":117,"type":86,"unit":30,"dose":119,"refs":121,"limits":123,"durationDays":126,"notes":129},"meningitis","bacterial-meningitis",{"fa":115,"en":116},"مننژیت — کودکان: ۱۰۰ mg\u002Fkg\u002Fday (حداکثر ۴ g\u002Fday)","Meningitis — children: 100 mg\u002Fkg\u002Fday (max 4 g\u002Fday)",{"maxAge":118},{"value":47,"unit":48},{"perKgPerDay":120,"dividedDoses":5},100,[122],{"source":34,"section":91},{"maxPerDay":57,"refs":124},[125],{"source":34,"section":91},{"min":127,"max":128},7,14,[130],{"text":131,"refs":134},{"fa":132,"en":133},"دوز اول ۱۰۰ mg\u002Fkg (حداکثر ۴ g)؛ سپس یک بار در روز یا دو نوبت هر ۱۲ ساعت. معمولاً وریدی و در بیمارستان.","First dose 100 mg\u002Fkg (max 4 g); then once daily or in two doses every 12 h. Usually IV in hospital.",[135],{"source":34,"section":91},[137],{"id":138,"severity":139,"text":140,"refs":143},"ci","block",{"fa":141,"en":142},"حساسیت به سفتریاکسون یا هر سفالوسپورین؛ نوزاد نارس تا سن پس از قاعدگی ۴۱ هفته؛ نوزاد ≤۲۸ روز که محلول کلسیم‌دار وریدی لازم دارد؛ تزریق وریدی محلول حاوی لیدوکائین.","Hypersensitivity to ceftriaxone or any cephalosporin; premature neonates up to 41 weeks postmenstrual age; neonates ≤28 days needing calcium-containing IV solutions; IV use of solutions containing lidocaine.",[144],{"source":34,"section":145},"Contraindications",[],[],[],[],{"status":151,"reviewer":152,"date":152},"unverified",null,[154,160,165,171,176,182],{"regimen":40,"formulation":24,"input":155,"expect":158},{"ageYears":156,"weightKg":157},40,70,{"perDose":51,"mlPerDose":159,"upperPerDose":52},4,{"regimen":68,"formulation":24,"input":161,"expect":164},{"ageYears":162,"weightKg":163},25,60,{"mlPerDose":5},{"regimen":79,"formulation":24,"input":166,"expect":169},{"ageYears":167,"weightKg":168},2,10,{"perDose":170,"mlPerDose":167},500,{"regimen":79,"formulation":24,"input":172,"expect":175},{"ageYears":173,"weightKg":174},8,30,{"perDose":51},{"regimen":97,"formulation":24,"input":177,"expect":180},{"ageYears":178,"weightKg":179},5,20,{"perDose":51,"upperPerDose":181},1500,{"regimen":112,"formulation":24,"input":183,"expect":184},{"ageYears":128,"weightKg":88},{"perDose":57},[186],"J01DD04",{"status":188,"forms":189,"refs":206},"registered",[190,194,198,202],{"code":191,"en":192,"fa":193},"00237","CEFTRIAXONE 1 GR VIAL","ویال سفتریاکسون ۱ گرم",{"code":195,"en":196,"fa":197},"00238","CEFTRIAXONE 250MG VIAL","ویال سفتریاکسون ۲۵۰ میلی‌گرم",{"code":199,"en":200,"fa":201},"13291","CEFTRIAXONE 2G  VIAL","ویال سفتریاکسون ۲ گرم",{"code":203,"en":204,"fa":205},"00239","CEFTRIAXONE 500MG VIAL","ویال سفتریاکسون ۵۰۰ میلی‌گرم",[207],{"source":208,"section":209,"url":210},"darooyab-generic","G-352\u002FCeftriaxone","https:\u002F\u002Fwww.darooyab.ir\u002FG-352\u002FCeftriaxone",[212,216,220,224,227],{"kind":213,"url":214,"label":215},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=065342","ANDA065342",{"kind":217,"url":218,"label":219},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=8351aa37-552d-471d-b293-c564dcb6ec29","FDA Ceftriaxone",{"kind":221,"url":222,"label":223},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa685032.html","Ceftriaxone Injection",{"kind":225,"url":226,"label":186},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=J01DD04",{"kind":228,"url":210,"label":8},"darooyab",{"pregnancy":230,"lactation":239,"pediatric":247,"geriatric":255},{"level":231,"text":232,"quote":235,"refs":236},"caution",{"fa":233,"en":234},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Because animal reproductive studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.",[237],{"source":34,"section":238},"Pregnancy",{"level":231,"text":240,"quote":243,"refs":244},{"fa":241,"en":242},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Caution should be exercised when ceftriaxone is administered to a nursing woman.",[245],{"source":34,"section":246},"Nursing Mothers",{"level":231,"text":248,"quote":251,"refs":252},{"fa":249,"en":250},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","Safety and effectiveness of ceftriaxone in neonates, infants and pediatric patients have been established for the dosages described in the DOSAGE AND ADMINISTRATION section.",[253],{"source":34,"section":254},"Pediatric Use",{"level":231,"text":256,"quote":259,"refs":260},{"fa":257,"en":258},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","Of the total number of subjects in clinical studies of ceftriaxone, 32% were 60 and over.",[261],{"source":34,"section":262},"Geriatric Use",{"kind":264,"refs":265,"id":215},"ANDA",[266],{"source":34,"section":267},"SPL approval \u002F marketing category",1792440729921]